Anti-JCV antibody index does not change during ocrelizumab-treatment. Issue 3 (September 2020)

• Record Type: Journal Article
• Authors: Rempe, Torge; Carlson, Aaron; Miravalle, Augusto; Gyang, Tirisham Victoria
• Is Part Of: Multiple sclerosis journal, experimental, translational and clinical. Volume 6:Issue 3(2020)
• Publication Date: 2020-09
• Subjects: JCV antibody index -- STRATIFY JCV -- ocrelizumab -- progressive multifocal leukoencephalopathy; Multiple sclerosis -- Periodicals; 616.834
• DOI: 10.1177/2055217320960510
• Languages: English
• ISSNs: 2055-2173

Abstract

Objective: To prospectively assess anti-JCV antibody index (AI) and its relationship to immunoglobulin levels in ocrelizumab-treated MS patients. Methods: Monocentric prospective observational study over 24 months assessing anti-JCV AI and immunoglobulin levels in MS patients before and after initiation of ocrelizumab. Results: No significant change in anti-JCV AI titers was observed 458 ± 300 days after initiation of ocrelizumab (n = 45, 0.7 ± 2.21 vs. 0.6 ± 2.06, p = 0.8). Seroconversion occurred in 1/20 initially anti-JCV seronegative patients. There was no correlation between changes in anti-JCV AI and immunoglobulins. Conclusion: Treatment with ocrelizumab is not associated with an increase in anti-JCV AI titers.